secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001701541-22-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics Q2 2022 net loss $22.9M; cash $160.9M, runway into Q3 2024
--------------------------------------------------------------------------------

- Net loss of $22.9M in Q2 2022, narrowing from $34.4M in Q2 2021.
- Cash and investments $160.9M as of June 30, 2022; expected to fund ops into Q3 2024.
- First patient dosed in Phase 1 study of BDTX-1535; clinical update expected in 2023.
- Appointed Sergey Yurasov as Chief Medical Officer in June 2022.
- IND submission for BDTX-4933 targeted for H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154122000028/0001701541-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154122000028/bdtx-20220809.htm
  HTML page:      https://secwatch.observer/filing/0001701541-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer